Feedback / Questions
vobarilizumab (ALX-0061) - Sanofi
Ablynx: Corporate Presentation
(Ablynx)
-
Oct 9, 2016 -
"Phase IIb combination therapy (+ MTX)"; "Up to 49% of patients in clinical remission at week 24"
P2b data
•
Immunology
http://www.ablynx.com/uploads/home/d2a7b156-9ac8-44d9-8974-288a5e8e2a39-ablynxcorporatepresentation_october2016_website.pdf
Oct 9, 2016
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious